Superwomen Report: Femtech’s promise for health equity and longevity

A new report has explored the future of femtech, and how innovation is redefining women’s health and longevity.

Women’s health has historically lagged behind men’s due to systemic inequities in research, representation, and care. Compounded with the recently accepted experience of medical gaslighting, these inequalities have created a system that often overlooks the complexity of women’s health needs, and fails to deliver equitable, effective solutions.

The new “Superwomen” report from Havas Health Network explores the current shift taking place in women’s health driven by innovation, technology and increased investment.

“Women’s health tech is experiencing an incredible surge of innovation and investment,” said Chloe Depiesse, head of digital strategy at Havas NOW.

“In the past few years, we’ve seen a wave of venture capital funding, a new generation of female entrepreneurs and investors, and millennial celebrities using their platforms to spotlight women’s health issues.

“Add to this a more empowered, informed female consumer, and we’re on the brink of a true revolution in women’s healthcare.”

The report touches on advances in technology that are transforming women’s health such as wearables and AI health monitoring systems which enable women to manage health more effectively, as well as innovations in longevity science that are enabling women to extend ovarian function, delay menopause and mitigate chronic conditions like osteoporosis and heart disease.

For example, the report highlights how Celmatix is leveraging bioengineering and nanotechnology to combat age-related fertility decline by developing devices and materials that enhance egg quality and ovarian function.

Women are seeing further reproductive support through organisation’s such as the UK’s Peanut, which provides an online community for women across each stage of fertility, pregnancy, motherhood, and menopause, as well as US-based Boram which provides a first-of-its-kind postnatal retreat with residential care packages for new mothers in the US.

“We’re at the beginning of important conversations about women’s health after childbirth, menopause, and the emotional and physical toll of these life stages,” said Divya Dileep, executive creative director at Jacques, which is part of the Havas Health Network.

The report further explores how GLP-1 medications, initially used for diabetes, are now being used by women to help manage their weight, and which are now showing promise for conditions such as Polycystic ovary syndrome.

All these advances are driven by increased investment in women’s healthcare, the report notes, highlighting that the market is expected to reach US$121bn by 2030.

“We’ve seen a surge in interest from VC funding and entrepreneurial innovation in women’s health,” said Depiesse.

“This is driven by a recognition of the historical under-investment in women’s health (only 2 per cent of the US$41.2bn in venture funding for health innovators in 2023 was allocated to women’s health) combined with recent societal movements like Roe v. Wade, legislative changes.

“In November 2023, President Joe Biden announced the first-ever White House Initiative on Women’s Health Research and the rise of female entrepreneurs and investors addressing women’s health issues.”

“Superwomen isn’t just about breakthroughs in innovation—it’s about creating equity and rewriting the narrative around women’s health care,” said Eric Weisberg, global chief creative officer at Havas Health Network.

“Technology and data are giving women greater agency over their health, enabling them to demand action and accountability from healthcare providers.”

To read the full report please visit: https://superhuman.havashealth.com/superwomen/